Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 2, 2003, Pages 283-295

  Moomaw, Michelle D ^a   Cornea, Paul ^b   Rathbun, R Chris ^a   Wendel, Karen A ^b,c  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Acyclovir; Famciclovir; Herpes simplex; Herpes zoster; Penciclovir; Valacyclovir

Indexed keywords

ACICLOVIR; ALLOPURINOL; ANTACID AGENT; ANTIVIRUS AGENT; BEHENYL ALCOHOL; CIDOFOVIR; CIMETIDINE; DIGOXIN; DNA; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; PENCICLOVIR; PLACEBO; PROBENECID; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; VALACICLOVIR; VALGANCICLOVIR; ZIDOVUDINE;

ADULT; AGE; BREAST CARCINOMA; BREAST MILK; CHRONIC PAIN; COST EFFECTIVENESS ANALYSIS; DELIRIUM; DIARRHEA; DISEASE ASSOCIATION; DISEASE DURATION; DNA SYNTHESIS INHIBITION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; GENITAL HERPES; HEADACHE; HEALING; HEMOLYTIC UREMIC SYNDROME; HERPES LABIALIS; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HUMAN; IMMUNOFLUORESCENCE TEST; IN SITU HYBRIDIZATION; LETHARGY; MEDICAL RESEARCH; MORBIDITY; NAUSEA AND VOMITING; NONHUMAN; POLYMERASE CHAIN REACTION; PREGNANCY; RECURRENT INFECTION; REVIEW; SEIZURE; SEROLOGY; SEXUAL TRANSMISSION; SYMPTOM; TERATOGENICITY; TESTIS DISEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TIME; TREMOR; VARICELLA ZOSTER VIRUS; VIRUS CULTURE;

EID: 3042823384     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.2.283     Document Type: Review

References (126)

1. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann. Intern. Med. 121(11), 847-854 (1994).
2. Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic shedding. J. Antimicrob. Chemother. 45(Suppl.) T3, 1-8 (2000).
3. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl Acad. Sci. USA 74(12), 5716-5720 (1977).
4. Derse D, Cheng YC, Furman PA, St Clair MH, Elion GB. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl) guanine triphosphate. Effects on primer-template function. J. Biol. Chem. 256(22), 11447-11451 (1981).
5. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J. Antimicrob. Chemother. 12(Suppl.) B29-37 (1983).
6. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother. 39(2), 2759-2764 (1995).
7. Burnette TC, Harrington JA, Reardon JE, Merrill BM, de Miranda P. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. J. Biol Chem. 270(26), 15827-15831 (1995).
8. Emmert DH. Treatment of common cutaneous herpes simplex virus infections. Am. Fam. Physician 61(6), 1697-706, 1708 (2000).
9. GlaxoSmithKline. Valtrex (valacyclovir). Product information brochure. Research Triangle Park, NC, USA, (2002).
10. Laskin OL, Longstreth JA, Whelton A et al. Effect of renal failure on the pharmacokinetics of acyclovir. Am. J. Med 73(1A), 197-201 (1982).
11. Posner J, Soul-Lawton J, Weller S et al. Valtrex (valaciclovir) - bioavailability in different patient populations. Can. J. Infect. Dis. 6(Suppl. C), 287C (1995) (Abstract).
12. Rolan PE, Maillot F, On NT, Posner J. The effects of cimetidine and probenecid on the conversion of a valine ester of acyclovir, 256U, to acyclovir and acyclovir renal clearance in healthy volunteers. Br. J. Clin. Pharmacol. 35, 533P (1993) (Abstract).
13. de Bony F, Bidault R, Peck R, Posner J. Lack of interaction between valaciclovir, the L-valyl ester of acyclovir and Maalox antacid. J. Antimicrob. Chemother. 37(2), 383-387(1996).
14. Soul-Lawton JH, Weatherley BC, Posner J, Layton G, Peck RW. Lack of interaction between valaciclovir, the L-valyl ester of aciclovir and digoxin. Br. J. Clin. Pharmacol. 45(1), 87-89 (1998).
15. Wang LH, Schultz M, Weller S, Smiley ML, Blum MR. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. Antimicrob. Agents Chemother. 40(1), 80-85 (1996).
16. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J. Infect. Dis. 186(Suppl. 1), S40-S46 (2002).
17. Mertz GJ, Eton L, Kaufman R et al. Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. Am. J. Med. 85(2A), 14-19 (1988).
18. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch. Intern. Med. 156(15), 1729-1735 (1996).
19. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 76(5), 369-380 (1997).
20. Rivaud E, Massiani MA, Vincent F, Azoulay E, Coudrec LJ. Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient. Arch. Intern. Med. 160(11), 1705-1706 (2000).
21. GlaxoSmithKline. Zovirax (acyclovir). Product information brochure. Research Triangle Park, NC, USA, (2001).
22. Stahlmann R, Klug S, Lewandowski C et al. Teratogenicity of acyclovir in rats. Infection 15(4), 261-262 (1987).
23. Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am. J. Obstet. Gynecol. 182(1 Pt 1), 159-163 (2000).
24. Frenkel LM, Brown ZA, Bryson YJ et al. Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am. J. Obstet. Gynecol. 164(2), 569-576 (1991).
25. Kimberlin DF, Weller S, Whitley RJ et al. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Am. J. Obstet. Gynecol. 179(4), 846-851 (1998).
26. Novartis Pharmaceuticals Corporation. Denavir (penciclovir). Product information brochure. East Hanover, NJ, USA, (2001).
27. Hodge RA, Perkins RM. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob. Agents Chemother. 33(2), 223-229 (1989).
28. Luber AD, Flaherty JF Jr. Famciclovir for treatment of herpesvirus infections. Ann. Pharmacother. 30(9), 978-985 (1996).
29. Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin. Pharmacokinet. 31(1), 1-8 (1996).
30. Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1- yl)guanine (BRL39123) in cell culture. Antimicrob. Agents Chemother. 31(8), 1238-1242 (1987).
31. Boyd MR, Bacon TH, Sutton D. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL39123) in animals. Antimicrob. Agents Chemother. 32(3), 358-363 (1988).
32. Novartis Pharmaceuticals Corp. Famvir (famciclovir). Product information brochure. East Hanover, NJ, USA (2002).
33. Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob. Agents Chemother. 33(10), 1765-1773 (1989).
34. Clarke SE, Harrell AW, Chenery RJ. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab. Dispos. 23(2), 251-254 (1995).
35. Pue MA, Pratt SK, Fairless AJ et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J. Antimicrob. Chemother. 33(1), 119-127 (1994).
36. Fowles SE, Pierce DM, Prince WT, Thow JC. Effect of food on the bioavailability of penciclovir, a novel antiherpes agent, following oral administration of the prodrug, famciclovir. Br. J. Clin. Pharmacol. 29, 620P (1990) (Abstract).
37. Fowles SE, Fairless AJ, Pierce DM, Prince WT. A further study of the effect of food on the bioavailability and pharmacokinetics of penciclovir after oral administration of famciclovir. Br. J. Clin. Pharmacol. 32, 657B (1991) (Abstract).
38. Fowles SE, Pierce DM, Prince WT, Staniforth D. The tolerance to and pharmacokinetics of penciclovir (BRL39, 123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. Eur. J. Clin. Pharmacol. 43(5), 513-516 (1992).
39. Boike SC, Pue MA, Freed MI et al. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin. Pharmacol Ther. 55(4), 418-426 (1994).
40. Pue MA, Boike SC, Freed MI et al. Pharmacokinetics of penciclovir in subjects with hepatic insufficiency following oral famciclovir. Br. J. Clin. Pharmacol. 37, 494P (1994) (Abstract).
41. Fairless AJ, Pratt SK, Pue MA et al. An investigation into the potential interaction between theophylline and oral famciclovir in healthy male volunteers. Br. J. Clin. Pharmacol 34, 171P-172P (1992) (Abstract).
42. Fowles SE, Pratt SK, Laroche J, Prince WT. Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. Eur. J. Clin. Pharmacol. 46(4), 355-359 (1994).
43. Pratt SK, Fowles SE, Pierce DM, Prince WT. An investigation of the potential interaction between cimetidine and famciclovir in nonpatient volunteers. Br. J. Clin. Pharmacol. 32, 656P (1991) (Abstract).
44. Pue MA, Saporito M, Laroche J et al. An investigation of the potential interaction between digoxin and oral famciclovir in healthy male volunteers. Br. J. Clin. Pharmacol. 36, 177P (1993) (Abstract).
45. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob. Agents Chemother. 38(10), 2454-2457 (1994).
46. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. 16(1), 114-128 (2003).
47. Reusser P. Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. J. Hosp. Infect. 33(4), 235-248 (1996).
48. Katz DH, Marcelletti JF, Khalil MH, Pope LE, Katz LR. Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. Proc. Natl Acad. Sci. USA 88(23), 10825-10829 (1991).
49. DeClercq E, Holy A. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice. Antimicrob. Agents Chemother. 35(4), 701-706 (1991).
50. Frank KB, Chiou JF, Cheng YC. Interaction of herpes simplex virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl) guanine triphosphate. J. Biol. Chem. 259(3), 1566-1569 (1984).
51. Schnurer J, Oberg B. Inhibitory effects of foscarnet on herpesvirus multiplication in cell culture. Arch. Virol. 68(3-4), 203-209 (1981).
52. Embil JA, Stephens RG, Manuel FR. Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Can. Med. Assoc. J. 113(7), 627-630 (1975).
53. Xu F, Schillinger JA, Sternberg MR et al. Seroprevalence and coinfection with herpes simplex virus Type 1 and Type 2 in the United States, 1988-1994. J. Infect. Dis. 185(8), 1019-1024 (2002).
54. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 186(Suppl. 1), S3-28 (2002).
55. Fiddian AP, Yeo JM, Stubbings R, Dean D. Successful treatment of herpes labialis with topical acyclovir. Br. Med. J. (Clin. Res. Ed.) 286(6379), 1699-1701 (1983).
56. Van Vloten WA, Swart RN, Pot F. Topical acyclovir therapy in patients with recurrent orofacial herpes simplex infections. J. Antimicrob. Chemother. 12(Suppl. B), 89-93 (1983).
57. Shaw M, King M, Best JM, Banatvala JE, Gibson JR, Maher MR. Failure of acyclovir cream in treatment of recurrent herpes labialis. Br. Med. J. (Clin. Res. Ed.) 291(6487), 7-9 (1985).
58. Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob. Agents Chemother. 46(7), 2238-2243 (2002).
59. Raborn GW, Martel AY, Lassonde M, Lewis MA, Boon R, Spruance SL. Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials. J. Am. Dent. Assoc. 133(3), 303-309 (2002).
60. Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. JAMA 277 (17), 1374-1379 (1997).
61. Sacks SL, Thisted RA, Jones TM et al. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: a multicenter, randomized, placebo-controlled trial. J. Am. Acad. Dermatol. 45(2), 222-230 (2001).
62. Habbema L, De Boulle K, Roders GA, Katz DH. n-Docosanol 10% cream in the treatment of recurrent herpes labialis:a randomised, double-blind, placebo-controlled study. Acta Derm. Venereol. 76(6), 479-481 (1996).
63. Raborn GW, McGaw WF, Grace M, Tyrrell LD, Samuels SM. Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study. J. Am. Dent. Assoc. 115(1), 38-42 (1987).
64. Spruance SL, Stewart JC, Rowe NH, McKeough MB, Wenerstrom G, Freeman DJ. Treatment of recurrent herpes simplex labialis with oral acyclovir. J. Infect. Dis. 161(2), 185-190 (1990).
65. Spruance SL, Jones TM, Blatter MM et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob. Agents Chemother. 47(3), 1072-1080 (2003).
66. Rooney JF, Straus SE, Mannix ML et al. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann. Intern. Med. 118(4), 268-272 (1993).
67. Baker D, Eisen D. Valacyclovir for prevention of recurrent herpes labialis: 2 double- blind, placebo-controlled studies. Cutis 71(3), 239-242 (2003).
68. Boon R, Goodman JJ, Martinez J, Marks GL, Gamble M, Welch C. Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: a randomized, double-blind, placebo-controlled trial. Clin. Ther. 22(1), 76-90 (2000).
69. Raborn GW, Martel AY, Grace MG, McGaw WT. Herpes labialis in skiers: randomized clinical trial of acyclovir cream versus placebo. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod 84 (6), 641-645 (1997).
70. Spruance SL, Hamill ML, Hoge WS, Davis LG, Mills J. Acyclovir prevents reactivation of herpes simplex labialis in skiers. JAMA 260(11), 1597-1599 (1988).
71. Evans TG, Bernstein DI, Raborn GW, Harmenberg J, Kowalski J, Spruance SL. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrob. Agents Chemoth. 46(6), 1870-1874 (2002).
72. Spruance SL, McKeough MB. Combination treatment with famciclovir and a topical corticosteroid gel versus famciclovir alone for experimental ultraviolet radiation-induced herpes simplex labialis: a pilot study. J. Infect. Dis. 181(6), 1906-1910 (2000).
73. Lowhagen GB, Tunback P, Andersson K, Bergstrom T, Johannisson G. First episodes of genital herpes in a Swedish STD population: a study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology. Sex. Transm. Infect. 76(3), 179-182 (2000).
74. Reeves WC, Corey L, Adams HG, Vontver LA, Holmes KK. Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N. Engl. J. Med. 305(6), 315-319 (1981).
75. Nilsen A, Myrmel H. Changing trends in genital herpes simplex virus infection in Bergen, Norway. Acta Obstet. Gynecol, Scand. 79(8), 693-696 (2000).
76. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N. Engl. J. Med. 333(12), 770-775 (1995).
77. Fleming DT, McQuillan GM, Johnson RE et al. Herpes simplex virus Type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337(16), 1105-1111 (1997).
78. Chapel TA, Brown WJ, Jeffres C, Stewart JA. How reliable is the morphological diagnosis of penile ulcerations? Sex. Transm. Dis. 4(4), 150-152 (1977).
79. O'Farrell N, Hoosen AA, Coetzee KD, van den EJ. Genital ulcer disease: accuracy of clinical diagnosis and strategies to improve control in Durban, South Africa. Genitourin Med. 70(1), 7-11 (1994).
80. Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm. Rep. 51(RR-6), 1-78 (2002).
81. Herpes Simplex Advisory Panel, Barton S, Brown D et al. 2001 National Guideline for the Management of Genital Herpes. Clinical Effectiveness Group. Ass. Genitourin. Med. Med. Soc. Venereal Dis. (2001). www.augm.org.uk/ceg2002/hsv0601.htm
82. Wald A. New therapies and prevention strategies for genital herpes. Clin. Infect. Dis. 28(Suppl. 1), S4-13 (1999).
83. Bryson YJ, Dillon M, Lovett M et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N. Engl. J. Med. 308(16), 916-921 (1983).
84. Fife KH, Barbarash RA, Rudolph T, DeGregorio B, Roth R. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. Sex. Transm. Dis. 24(8), 481-486 (1997).
85. Mertz GJ, Critchlow CW, Benedetti J et al. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 252(9), 1147-1151 (1984).
86. Nilsen AE, Aasen T, Halsos AM et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 2(8298), 571-573 (1982).
87. Reichman RC, Badger GJ, Mertz GJ et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 251(16), 2103-2107 (1984).
88. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. JAAM 276(1), 44-49 (1996).
89. Tyring SK, Douglas JM Jr, Corey L, Spruance SL, Esmann J. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch. Dermatol. 134(2), 185-191 (1998).
90. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin. Infect. Dis. 34(7), 958-962 (2002).
91. Strand A, Patel R, Wulf HC, Coates KM. Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. Sex. Transm. Infect. 78(6), 435-439 (2002).
92. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus Type 2 infection. Clin. Infect. Dis. 34(7), 944-948 (2002).
93. Diaz-Mitoma F, Sibbald RG, Shafran, SD, Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA 280(10), 887-892 (1998).
94. Reitano M, Tyring S, Lang W et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J. Infect. Dis. 178 (3), 603-610 (1998).
95. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus Type 2 with acyclovir. Ann. Intern. Med. 124(1 Pt 1), 8-15 (1996).
96. Schacker T, Hu HL, Koelle DM et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann. Intern. Med. 128(1), 21-28 (1998).
97. Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency overtime. Ann. Intern. Med. 131 (1), 14-20 (1999).
98. Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex. Transm. Infect. 75(6), 398-402 (1999).
99. Corey L, Tyring S, Beutner K et al. Once Daily Valacyclovir Reduces Transmission of Genital Herpes. 42nd Interscience Conf. Antimicrob. Agents Chemother. (2002) (Abstract LB-3).
100. Schacker T, Ryncarz, AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 280(1), 61-66 (1998).
101. Stamm WE, Handsfield HH, Rompalo AM, Ashley RL, Roberts PL, Corey L. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 260 (10), 1429-1433 (1988).
102. Brown ZA, Benedetti J, Selke S, Ashley R, Watts DH, Corey L. Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: relationship to preterm labor. Obstet. Gynecol. 87(4), 483-488 (1996).
103. Brown ZA, Selke S, Zeh J et al. The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med 337(8), 509-515 (1997).
104. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD Jr. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obster. Gynecol. 87(1), 69-73 (1996).
105. Brocklehurst P, Kinghorn G, Carney O et al. A randomised placebo-controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br. J. Obstet. Gynaecol. 105(3), 275-280 (1998).
106. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD Jr. Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect. Dis. Obstet. Gynecol. 10(2), 71-77 (2002).
107. Reyes M, Shaik NS, Graber JM et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch. Intern. Med. 163(1), 76-80 (2003).
108. Straus SE, Ostrove JM, Inchauspe G et al. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment and prevention. Ann. Intern. Med. 108(2), 221-237 (1988).
109. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch. Intern. Med. 155(15), 1605-1609 (1995).
110. Ragozzino MW, Melton LJ, III, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 61(5), 310-316 (1982).
111. Dworkin RH, Nagasako EM, Johnson RW, Griffin DR. Acute pain in herpes zoster: the famciclovir database project. Pain 94(1), 113-119 (2001).
112. Bezold GD, Lange ME, Gall H, Peter RU. Detection of cutaneous varicella zoster virus infections by immunofluorescence versus PCR. Eur. J. Dermatol. 11 (2), 108-111 (2001).
113. Espy MJ, Teo R, Ross TK et al. Diagnosis of varicella-zoster virus infections in the clinical laboratory by LightCycler PCR. J. Clin. Microbiol. 38(9), 3187-3189 (2000).
114. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br. Med. J. (Clin. Res. Ed.) 293(6561), 1529-1532 (1986).
115. Wood MJ, Ogan PH, McKendrick MW, Care CD, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am. J. Med. 85(2A), 79-83 (1988).
116. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. NZ Med. J. 102(863), 93-95 (1989).
117. Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J. Infect. Dis. 80 (Suppl.), 62-68 (1991).
118. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adul is. Antimicrob. Agents Chemother. 39(7), 1546-1553 (1995).
119. Colin J, Prisant O, Cochener B, Lescale O, Rolland B, Hoang-Xuan T. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 107(8), 1507-1511 (2000).
120. Tyring S, Barbarash RA, Nahlik JE et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo- controlled trial. Ann. Intern. Med. 123(2), 89-96 (1995).
121. Tyring S, Engst R, Corriveau C et al. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br. J. Ophthalmol 85(5), 576-581 (2001).
122. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch. Family Med. 9(9), 863-869 (2000).
123. Whitley RJ, Weiss H, Gnann JW, Jr., Tyring S, Mertz GJ, Pappas PG et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. Ann. Intern. Med 125(5), 376-383 (1996).
124. Wood MJ, Johnson RW, McKendrick MW et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N. Engl J. Med 330(13), 896-900 (1994).
125. Jacobson MA, Berger TG, Fikrig S et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 112(3), 187-191 (1990).
126. Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann. Intern. Med 1300(11), 922-932 (1999).